Catabasis Pharmaceuticals, Inc. announced that it has named Andrew A. Komjathy as Chief Commercial Officer. He brings to the company more than 30 years of experience in commercial operations and sales including extensive experience in rare diseases. He brings deep rare disease and commercial experience, most recently from his role as Vice President, Commercial Sales at Alkermes, Inc. He has also held senior level commercial operating positions in the U.S. Multiple Sclerosis Business Unit at Genzyme, in the North American and Asia-Pacific regions for Shire Human Genetic Therapies, as Shire Global Franchise Leader for Fabry/Gaucher in Switzerland, and at Biogen.